Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 624

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 624
---
 majority of operations of TuHURA. Total assets held by Legacy TuHURA and Kintara as of September 30, 2024 were $27,113 thousand and $4,140 thousand, respectively, as noted below, and included cash and cash equivalents held by Legacy TuHURA of $19,596 thousand and cash and cash equivalents of $3,020 thousand held by Kintara at September 30, 2024. After the Kintara Closing, the combined operations were primarily Legacy TuHURA’s operations with the focus mainly on Legacy TuHURA’s in-processresearch and development assets. As a result of Legacy TuHURA being treated as the acquiring company for financial reporting purposes, the historical financial statements of Legacy TuHURA are the historical consolidated financial statements of TuHURA. It is noted that the Kintara chief executive officer was not an assumed employee of TuHURA and as such was not a part of the assembled workforce of TuHURA following the Kintara Closing. TuHURA is in the process of conducting a study on REM-001,a second-generation PDT photosensitizer agent and which study is designed to determine whether a dose of REM-001lower than 1.2 mg/kg elicits a treatment effect similar to that seen in prior studies of REM-001at the 1.2 mg/kg dose and optimize the design in advance of a phase 3 trial. As noted in a Contingent Value Rights Agreement between TuHURA and a rights agent (the “CVR Agreement”), TuHURA is contractually obligated to use commercially reasonable efforts until December 31, 2025 to achieve the Milestone (defined below and in the CVR Agreement). TuHURA anticipates the successful enrollment of the ten cutaneous metastatic breast cancer patients and that such patients will complete the required follow-upto complete the trials in accordance with the CVR Agreement (the “Milestone”). The issuance of shares of TuHURA Common Stock upon the achievement of the Milestone is not contingent on any future outcome of clinical trials, commercialization, or economic benefit to be derived from the REM-001Study. TuHURA’s management has concluded that it is probable that the Milestone will be achieved and shares of TuHURA Common Stock will be issued. The REM-001Study is currently in the early stages of the study process with no clinical trials passed or proven efficacy. Once 10 patients are enrolled and tracked in the REM-001Study to determine whether a